

Archives  
(Healy Collection)  
November 19, 2015

**CURRICULUM VITAE**  
**Prepared March 2015**

**DAVID HEALY, MD FRCPsych**  
**North Wales Department of Psychological Medicine**  
**Hergest Unit, Ysbyty Gwynedd,**  
**BANGOR,**  
**Gwynedd LL57 2PW,**  
**Wales (UK)**  
**Tel: (1248) 384452**  
**Fax: (1248) 371397**  
**E-Mail: [David.Healy54@googlemail.com](mailto:David.Healy54@googlemail.com)**

**Citizenship: Republic of Ireland**  
**Country of Residence: UK**

**APPOINTMENTS**

January 2014	Professor of Psychiatry, Bangor University
November 2004	Professor of Psychiatry, Cardiff University
March 2004	Adjunct Professor in Centre for Social and Community Research Murdoch University, Perth, March 2004 – February 2007
April 2001/05	Visiting Professor, University of Toronto Faculty of Medicine
June 2000	Appointed Professor of Psychiatry, University of Toronto Head of the Mood & Anxiety Disorders Program.
Feb 1996	Reader in Psychological Medicine Division of Psychological Medicine, University of Wales College of Medicine (UWCM).
Feb 1992	Director, North Wales Department of Psychological Medicine (UWCM).
Jan 1990	Senior Lecturer in N Wales Dept of Psychological Medicine Division of Psychological Medicine University of Wales College of Medicine (UWCM), & Honorary Consultant in Psychiatry, Gwynedd

## **EDUCATION**

**Medical Education:** University College Dublin, 1973-1979, MB BCh BAO  
1st Medical Class Prize & Scholarship  
MD (PhD in US) awarded in December 1986

**Psychiatric Training:** Member Royal College of Psychiatrists - Spring 1985  
Fellow Royal College of Psychiatrists - Spring 1996

## **PRE-MEMBERSHIP EXPERIENCE**

July 1979 – June 1980 Internship Mater Hospital Dublin

July 1980 – June 1984 Research Fellow Dept of Pharmacology,  
University College Galway - MD thesis  
& Senior House Officer, Dept of Psychiatry, Galway

July 1984 Registrar in St Patrick's Hospital, Dublin

July 1985 MD write up.

## **POST-MEMBERSHIP EXPERIENCE**

Jan 1986 Registrar St Mary's Hospital, Castlebar

April 1986. Clinical Research Associate, Dept of Psychiatry,  
University of Cambridge Clinical School  
& Honorary Senior Registrar

April 1988 Senior Registrar in Psychogeriatrics  
with Drs C P B Brook and E Tym

May 1989 Locum Consultant Psychogeriatrician,  
Fulbourn Hospital, Cambridge

Sept 1989 Senior Registrar in Adult Psychiatry in Norwich

Jan 1990 Locum Cons Norwich, responsible for Substance Abuse

## **ROYAL COLLEGE of PSYCHIATRISTS ACTIVITIES**

Senior Organiser MRCPsych exam 1991-1993

Scheme Organiser for Senior/Specialist Registrars 1992-1997.

MRCPsych Part I examiner

College representative on Appointment Committees

Assessor of Membership Research Projects

## **RESEARCH TRAINING**

MD thesis commenced August 1980,

Supervised by Brian Leonard, Prof. of Pharmacology, U College, Galway  
 & Directed by Professor T B Counihan, Dept of Medicine, U College, Dublin.  
 Thesis "Biochemical Correlates of Depression" submitted Dec 1985  
 A study of platelet 5HT uptake and 5HT induced aggregation responses, platelet alpha adrenoceptor binding and lymphocyte beta adrenoceptor binding in depression.

Clinical Research Associate - Dept of Psychiatry, Cambridge, April 86 - March 88  
 Funded by a Wellcome Trust Major Grant Award: Biological Markers in Depression.  
 My Cambridge research also included work on concentration & memory in depression

## FOUNDATIONS

Founder and Board Member Centre for Data Based Medicine: 2010 to present  
 Board Member Foundation for Excellence in Mental Health: 2010 to present  
 Founder and Board member Data Based Medicine Limited: 2010 to present

Data Based Medicine aims at facilitating patient adverse event reporting and provision of state of the art consumer information using website technology RxISK.org. This is a multinational collaboration with multidisciplinary input across primary care, general medicine, psychiatry, pharmacology, pharmaco-epidemiology, genetics and anthropology as well as across the primary-secondary care interface and is linked to the WHO Uppsala Monitoring Centre for pharmacovigilance. The platform will provide opportunities for epidemiological investigations, genetic studies, drug discovery, and a range of opportunities to explore sociological/ anthropological issues in qualitative studies and the aim is to have the Centre for Data Based Medicine as a self funding institute with links to a major academic institution.

## RESEARCH GRANTS

1. Research Fellowship Dept of Pharmacology, U Coll Galway, 1980-82.
2. MRC Ireland Research Grant to investigate circadian variations in biological markers in depression, 1982-1984.
3. Research Fellow 1986 to 1988; Wellcome Trust Major Grant Award held by Prof E S Paykel in Cambridge.
4. Grant holder from the Welsh Scheme for Health & Social Services Research for a Cognitive Therapy of Delusions, Jan 1992 to Jan 1994, £43,000.
5. Grant holder Clwyd H.A.: Cognitive Therapy of Delusions; £50,000.
6. Grant holder Wellcome Trust for equipment for investigating the cognitive neuropsychology of neuroleptic drugs. £5,000.
7. Grant holder SmithKline Beecham for work on the cognitive neuropsychology of drugs active on the 5HT system. £50,000.
8. Clinical trial of a 5HT-1A agonist in depression, Duphar, £25,000.
9. Co-Holder of a MRC/Welsh Office/NW Reg H Authority Grant with R Bentall, R Stevenson and J Day (U of Liverpool), A Rogers (U of Manchester) G9322371, A multidisciplinary study of the management of neuroleptic medication in schizophrenia: educational and collaborative approaches. 1994-1998, £300,000.
10. Collaborator with M Jones and P Michael (UWB) on a Wellcome Trust Grant to research the history of the North Wales Hospital 1992-1995.

11. Co-holder Wellcome Trust Grant with Dr M Fraser and Professor N Rose, Dept of Sociology, Goldsmith's College London, Ethical Aspects of Psychiatric Drug Development, £88,000. Grant no. 065209/Z/01/Z/CM/CD/SW, 2001-2004.
12. Co-holder with Professor E Shorter, Dept of History, U of Toronto, of a Canadian Institutes of Health Research grant 116654: "The renewal of the pharmacopoeia for mood and anxiety 1966-2003", \$312,000: 1.10.03 to 30.09.06.
13. Coholder with Mark Rapley: Medicating the Unruly Child: A genealogy of ADHD, = \$AUS18, 500, MU Research Excellence Grants Scheme, no #.
14. Coholder with F Bayliss, J Downey et al States of Mind: Emerging issues in Neuroethics, Canadian Institutes of Health Research. Spring 2006, NNF 80045, Can \$1,376,500.
15. Holder grant on Toxoplasmosis infection in psychosis from Stanley Medical Research Foundation, granted Summer 2007, \$300,000.
16. Co-Holder with Dr S Linden, War trauma and mental illness: Psychopathology and the natural histories of patients admitted to the North Wales Asylum during WWI. Reference: SG090329
17. Data Based Medicine Development Funds: \$500,000.

### **MEMBERSHIP OF SOCIETIES**

Royal College of Psychiatrists - 1985.

Fellow - 1996.

British Association of Psychopharmacology -

Council Member & Hon Asst Secretary, 1989-1992

Secretary 1992-1995

Member of the Association of European Psychiatrists.

Member of European College of Neuropsychopharmacology

Fellow of Collegium Internationale Neuropsychopharmacologium

Member of the History Group Royal College of Psychiatrists

Member of the European Association for the History of Psychiatry

Member of the History Section of the World Psychiatric Association

Secretary 2009 ongoing.

Member of the European Society for Chronobiology

Member Advisory Board of European College of Study Methods in Clinical Trials

Member of ECNP working party for the History of Neuropsychopharmacology

Associate of BIOS: Centre for the study of Bioscience, Biomedicine, Biotechnology and Society at the London School of Economics and Political Science

### **DISTINCTIONS**

- First Mental Health Foundation Essay Prize for 1988
- Awarded a CINP Rafaelson Scholar Award in 1988
- Keynote Speaker at 30<sup>th</sup> Annual RANZCP Meeting - May 1995.
- Visiting Lecturer at the Clarke Institute of Psychiatry & Guest Lecturer on the History of Medicine Program, Univ. of Toronto, October 1995.
- Chair Wellcome Trust Witness Seminar March 1997.
- Guest Lecturer. 7<sup>th</sup> Japanese Clin Neuropharmacology Assoc. Tokyo, Nov 1997.
- Invited Lecture – American Psychopathological Association March 1999.

- Annual Raths-Steiger Lecture, Collegium Helveticum, ETH Zurich June 1999.
- Distinguished Guest Lecture, Dept of Psychiatry, Oslo, March 2000.
- Eric T Carlsson Memorial Grand Rounds, Cornell University, N York, Dec 2000
- Annual MIND-Institute of Psychiatry Lecture, February 2002.
- Bartlett Visiting Professorship, U of Rochester, N York, Nov 2003.
- Studium Generale Lecture Groningen April 2005
- Chancellor's Distinguished Guest Lecture, Louisiana State University Oct 2005
- ACNP Oakley Ray Annual Lecture on History of Psychopharmacology 2008
- Studium Generale Lecture Gent, February 2012

### **JOURNAL REVIEWER FOR:**

1. Academic Medicine
2. Acta Psychiatrica Scandinavia
3. Annals of Internal Medicine
4. Anthropology and Medicine
5. Archives of General Psychiatry
6. Australasian Psychiatry
7. Behavioural Pharmacology
8. British Journal of Psychiatry
9. British Journal of Clinical Pharmacology
10. British Journal of Hospital Medicine
11. British Medical Journal
12. Biological Psychiatry
13. Biomedical Central
14. Bipolar Disorders
15. BMJ Case Reports
16. BMJ Evidence Centre
17. Bulletin of History of Medicine
18. Business History Review
19. Canadian Medical Association Journal
20. Chemical Heritage
21. Chronobiology International
22. Clinical Practice & Epidemiology in Mental Health
23. CNS Drugs
24. Contemporary Psychology
25. Culture, Medicine & Psychiatry
26. Current Medical Research & Opinion
27. Current Anthropology
28. Depression and Anxiety
29. Disease Management & Health Outcomes
30. European Neuropsychopharmacology
31. Evidence Based Mental Health
32. Expert Review of Neurotherapeutics
33. Harvard Review of Psychiatry
34. Hastings Center Report
35. History of Psychiatry
36. History of Psychology

37. History of the Human Sciences
38. Human Psychopharmacology
39. International Journal of Geriatric Psychiatry
40. International Journal of Clinical Medicine
41. International Journal of Clinical Psychopharmacology
42. International Journal of Law and Psychiatry
43. International Journal of Neuropsychopharmacology
44. International Journal of Psychiatry in Clinical Practice
45. Internet Journal of Mental Health
46. Irish Journal of Medical Science
47. Irish Journal of Psychological Medicine
48. Journal of Abnormal Psychology
49. Journal of Affective Disorders
50. Journal of Attention Disorders
51. Journal of Child Psychology and Psychiatry
52. Journal of Clinical Psychiatry
53. Journal of the History of the Behavioral Sciences
54. Journal of Mental Deficiency Research
55. Journal of Nervous & Mental Disease
56. Journal of Mental Health
57. Journal of Personality & Social Psychology
58. Journal of Psychiatry & Neuroscience
59. Journal of Royal Society of Medicine
60. Journal of Sex and Marital Therapy
61. Journal of Social and Clinical Psychology
62. Journal of Psychopharmacology
63. Lancet
64. Life Sciences
65. MD Adviser
66. Medical History
67. Medical Hypotheses
68. Mens Sana Monographs
69. Monash Bioethics Review
70. Nature Medicine
71. Nature Neuroscience
72. Neuropsychiatric Disease & Treatment
73. Neuropsychopharmacology
74. Perspectives in Biology & Medicine
75. Pharmacogenomics.
76. Pharmacology, Biochemistry & Behaviour
77. Philosophy, Psychology & Psychiatry
78. Philosophy, Ethics and Humanities in Medicine
79. PLoS Medicine
80. PLoS One
81. Primary Care Psychiatry
82. Progress in Neuropharmacology & Biological Psychiatry
83. Psychiatric Bulletin
84. Psychiatry Research
85. Psychological Medicine
86. Psychology & Psychotherapy
87. Psychopharmacology

88. Psychosis
89. Psychotherapy & Psychosomatics
90. Public Library of Science: Medicine
91. Public Library of Science: One
92. Quarterly Journal of Mental Health
93. R&D Management
94. Science & Engineering Ethics
95. Science Studies
96. Social History of Medicine
97. Social Science and Medicine
98. Social Studies of Science
99. Studies in History and Philosophy of Biological and Biomedical Sciences
100. The Hedgehog Review
101. The Psychologist
102. Transcultural Psychiatry
103. World Psychiatry

**ASSESSOR FOR:**

- 1/ Agence d'évaluation des technologies et des modes d'intervention en santé de Québec.
- 2/ American Psychological Association:  
Guidelines on the Treatment of Children & Adolescents.
- 3/ Royal Australian College of Physicians:  
Revision of guidelines for ethical relationships between physicians and industry
- 4/ Royal College of Psychiatrists:  
Revision of guidelines on relationships between physicians and the pharmaceutical industry

Drugs and Therapeutics Bulletin  
Fullbright Fellowship Program  
Health Which?  
Medicine's Resource Centre Bulletin  
Welsh Health Gains Initiative

**UNIVERSITY PRESS & PUBLISHER REVIEWS**

1. Anansi Press
2. Basic Books
3. Bloomsbury USA
4. Bodley Head
5. Cambridge University Press
6. Chapman & Hall
7. Columbia University Press
8. Duke University Press
9. Encyclopedia of Social Measurement – Elsevier
10. Harvard University Press
11. Hodder & Arnold
12. Johns Hopkins University Press
13. Martin Dunitz Press.

14. New York University Press
15. Oxford University Press
16. Pantheon Books
17. Praeger Publishers
18. Random House
19. Routledge
20. Simon & Shuster
21. St Martins' Press
22. Times Literary Supplement
23. University of California Press.
24. University of Regina Press
25. University of South Carolina Press
26. Vanderbilt University Press

### **EDITORIAL BOARD**

Human Psychopharmacology	1990 – 2000
Primary Care & Community Psychiatry	1995 – 2005
History of Psychiatry	2002 – Associate Editor 2012
Medical Hypotheses	2003 – 2010
Mens Sana Monographs	2007 –
Psychosis	2007 –

### **GRANT REVIEWER**

1. ESRC
2. Canadian Institutes of Health Research
3. MacArthur Fellowship Reviewer
4. Medical Research Council of Canada
5. Medical & Social Science Research Board
6. Mental Health Foundation
7. National Institute for Health Research
8. National Lotteries Charities Board
9. National Science Foundation
10. Scottish Health Board
11. Social Sciences & Humanities Research Council of Canada
12. Wellcome Trust
13. Welsh NHS Research and Development Board

### **Academic Promotion Review**

1. Renselaar Polytechnic Institute
2. Trent University
3. University of California, Los Angeles

### **GOVERNMENT CONSULTANT**

Medical and HealthCare Devices Regulatory Agency (UK) 2001-2004 on SSRIs  
Senator Grassley's Office US re SSRIs  
Congressmen Barton and Greenwood US re SSRIs



House of Commons Health Select Cttee on the Influence of the Pharmaceutical Industry.  
Comité d'évaluation des pratiques médicales en matière de médicaments (Belgium)

### **INVITED PRESENTATIONS**

1. Functional variations in platelet rich plasma - Irish Blood Club, September 1981
2. A serotonin receptor assay - Irish Blood Club, Sept 1982
3. The role of adrenergic receptors in mental illness - Irish Neurosciences Group, March 1983.
4. Ambiguities in the uptake of 5HT in platelets from both depressed patients and from controls - Irish Neurosciences Group, October 1984.
5. Two Crows sitting on a Fence - Irish Neurosciences Group, March 1985.
6. Platelet & Neuroendocrine studies in Depression - Irish Neurosciences Group, March 1987.
7. Biochemical Markers in Depression - Pontedilegno Workshop on Membrane Mechanisms in Synaptic Transmission, June 1982 (poster).
8. The Uptake of Serotonin in Depression - Royal College of Psychiatrists, July 1983.
9. Is 5HT induced platelet aggregation a useful index to depression? - British Pharmacological Society, September 1983.
10. Serotonergic Markers in Depression - Brain and Behaviour Workshop, Zuoz, January 1984 (poster).
11. Abnormalities in the Circadian Regulation of 5HT Uptake into the Platelets of Depressed Persons - 14th CINP, Florence, June 1984.
12. Use of a Microcomputer to rate Depression in a West of Ireland Population - 14th CINP, Florence, June 1984 (poster).
13. Rhythm and Blues - Invited Speaker to Symposium on Recent Advances in Biological Psychiatry, Queens University, Belfast, September 1985.
14. Normal and Abnormal Variations in Platelet 5HT Uptake from Control and Depressed Populations - Royal College of Psychiatrists, November 1985.
15. One Hundred and One Uses for a Dead Psychiatrist. Invited Speaker at a Symposium on Animal Models of Depression, BAP Summer Meeting, Cambridge 1987.
16. Mourning, Melancholia and Mood-Altering Drugs - Invited Speaker at a BAP Symposium on Current Developments on Psychopharmacology, in Birmingham, Spring 1988.

17. The effect of treatment with and withdrawal from antidepressants on platelet 3H Imipramine binding in volunteers. BAP Cambridge 1988.
18. Rhythm and Blues - Invited Speaker at a BAP Symposium "Thirty Years Since Imipramine" in Galway, September 1988.
19. Plasma noradrenaline (NA), adrenaline (A) and DHPG levels in depression before and after clonidine. Spring Quarterly Meeting of Royal College of Psychiatrists, Galway, 1990.
20. Antidepressant induced suicidal ideation. Free Communications BAP Annual General Meeting, York 1991.
21. Acid Alpha-1 Glycoprotein levels in Depression. Free Communications, BAP Annual General Meeting, York 1991.
22. Altered States of Consciousness: Phenomenology and Pharmacology. BAP Annual General Meeting York 1991, Invited Speaker.
23. Clinical Chickens and Marketing Eggs. BAP Spring Meeting, North Wales 1992, Invited Speaker.
24. Endogenous Rhythms and Reactive Clocks. BAP Annual General Meeting Cambridge 1992, Invited Speaker.
25. Neuropsychology, Pharmacopsychology and Schizophrenia. Second International Symposium on Schizophrenia, Maastricht Nov 1992.
26. The Enigma of Irish Psychiatry. European Association for the History of Psychiatry, Third General Meeting London August 1993.
27. The Role of Drug Treatment in Psychiatric Rehabilitation. Third World Congress for Psychosocial Rehabilitation, Dublin Sept. 1993.
28. The Enigma of Irish Psychiatry. Third World Congress for Psychosocial Rehabilitation, Dublin Sept. 1993.
29. Altered Circadian Rhythms and Depression. European Society for Chronobiology 9th Annual Meeting, Bath, September 1993.
30. The Marketing of Psychotropic Drugs: How the Industry Gets it Right. BAP Winter Meeting, Nov 1993.
31. Healthy Volunteer Research in Psychopharmacology. Milford Symposium IV, Univ of Surrey Guildford January 1994.
32. Psychiatry, Psychotherapy and the Future of Mental Health Services in Primary and Secondary Care. Royal Society of Medicine, Section of General Practice. Jan 1994.
33. Human Psychopharmacological Research with Healthy Volunteers: Problems and Opportunities. BAP Spring Meeting, Birmingham 1994.

34. The Psychological Management of Schizophrenia: Problems and Opportunities. Royal College of Psychiatrists Annual General Meeting Cork 1994.
35. Psychotropic Medication and compliance: a patient-centred approach. Twentieth European Conference on Psychosomatic Medicine, Gent, August 1994.
36. The Industrialisation of Psychiatric Language. Royal College of Psychiatrists. Winter Meeting, Glasgow, 1995.
37. The Role of Abuse in Psychiatric Presentations. Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Post Douglas Preconference Symposium, May 1995.
38. The psychotherapy of psychosis. Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Cairns, May 1995.
39. The evaluation of psychotherapies. Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Cairns, May 1995.
40. Horizons in addiction therapy. Addiction Section of Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Hamilton Island May 1995.
41. The Discovery of the Antidepressants to the History of Medicine Department, University of Toronto, October 1995.
42. The Influence of Pharmaceutical Developments on Psychiatric Nosology, To the Clarke Institute of Psychiatry - Visiting Lecturer, October 1995.
43. Negative Priming and Psychosis, CINP Melbourne, June 1996.
44. The Invention of Antidepressants, AEP and Royal College of Psychiatrists Meeting London, July 1996.
45. Negative priming in healthy volunteers after neuroleptics, minor tranquillisers and ketamine and in treated and untreated psychotic subjects. ACNP, Dec 1996 (poster).
46. Rhythm & Blues. British Psychological Society, Winter Meeting, London Dec 1996.
47. Innovation in Drug Treatment. NHS Executive (West Midland), Commissioning and Provision of Services for the Severely Mentally Ill. Birmingham March 1997.
48. Wellcome Witness Seminar on The Impact of Psychopharmacology on Psychiatry, March 1997 (serial contributions).
49. The Church, Nationalism and Mental-Illness in Early Twentieth Century Ireland. Wellcome Trust Specialist Seminar on Asylums, Trinity College Dublin June 30th 1997.
50. The Enhancement of Social Functioning as a Therapeutic Principle in the Treatment of Depression. Satellite Symposia at Royal College of Psychiatrists Summer Meeting, Bournemouth 1997

51. The Enhancement of Social Functioning as a Therapeutic Principle in the Treatment of Depression. Satellite Symposia at BAP Annual Meeting Cambridge 1997
52. The Enhancement of Social Functioning as a Therapeutic Principle in the Treatment of Depression. ECNP Annual Meeting Vienna, Sept 1997
53. Methods of Rating Depression in Clinical Trials. 7th Japanese Clinical Neuropharmacology Association meeting. Tokyo, Nov 1997.
54. The Invention of Depression. Scottish Division of Royal College of Psychiatrists, Winter 1998.
55. Does Technology Drive History. Enhancement Technologies Research Group Seminar, University College London, Feb 1998.
56. New Drugs and Old Problems, Mind Conference, London, April 1998.
57. Social Functioning in Depression. Scandinavian Society for Psychopharmacology, Copenhagen, April 1998.
58. Reboxetine, the first selective norepinephrine reuptake inhibitor. American Psychiatric Association Meeting, Toronto, June 1998, New Research Symposium abst NR 228.
59. Physical Treatments in Psychiatry Before 1948. Royal College of Psychiatrists Annual General Meeting, Belfast June 1998.
60. Hallucinations and Psychopharmacology, Invited Symposium Speaker, BAP Annual Meeting, Cambridge July 1998.
61. The History of the Antidepressants, in XX1st CINP Meeting, Glasgow July 1998.
62. The Role of Consensus Statements on Psychotropic Drugs in Therapeutics in Learning Disabilities Conference, Nottingham November 1998.
63. The Antidepressant Project. American Psychopathological Association Meeting, New York, March 1999.
64. The Antidepressant Era, The Annual Raths-Steiger lecture, Zurich, June 1999.
65. Modelling suicide risk in primary care primary affective disorders. British Association of Psychopharmacology Annual Meeting Harrogate July 25<sup>th</sup> 1999 (poster).
66. History of the Treatment of the Schizophrenias, World Psychiatric Association meeting History of Psychiatry Section Symposium, Hamburg August 1999.
67. The rational basis for prescribing antidepressants. European College of Neuropsychopharmacology London, Sept 1999.
68. Neuroleptic Discontinuation Syndromes. United Kingdom Psychiatric Pharmacists Annual Meeting, November 1999.

69. The expansion of the therapy industry in North Wales: 1896 and 1996 compared. St David's Day Conference – Health and Medicine in Wales.
70. Discovery and Development of the Antidepressants: What the History Books won't tell you. McLean Hospital Psychopharmacology Service, Harvard University Boston, March 24<sup>th</sup> 2000.
71. Psychopharmacology and the Disease Concept. Oslo Department of Psychiatry Annual Psychiatry Symposium, March 31<sup>st</sup> 2000.
72. Beyond the Disease Concept. Oslo Department of Psychiatry Annual Psychiatry Symposium, March 31<sup>st</sup> 2000.
73. Antidepressant Associated Suicidality (poster). This was presented at The Royal College of Psychiatrists meeting in July 2000.
74. Antidepressant Associated Suicidality (poster). The British Association of Psychopharmacology meeting in July 2000
75. Antidepressant Associated Suicidality (poster). The European College of Neuropsychopharmacology in Munich Sept 2000.
76. Better than Well on Antidepressants (poster). This was presented at The Royal College of Psychiatrists meeting in July 2000,
77. Better than Well on Antidepressants (poster). The British Association of Psychopharmacology meeting in July 2000
78. Better than Well on Antidepressants (poster). The European College of Neuropsychopharmacology in Munich Sept 2000.
79. The Social Adaptation Self-evaluation Scale: Effects of antidepressants (poster). This was presented at The Royal College of Psychiatrists meeting in July 2000.
80. The Social Adaptation Self-evaluation Scale: Effects of antidepressants (poster). The European College of Neuropsychopharmacology in Munich Sept 2000.
81. Let Them Eat Prozac. Centre for Freudian Analysis & Research, London, October 2000.
82. The Interface between Psychopharmacology & Society: 1952-2002. In Looking Back, Looking Ahead. Psychiatry in the 21<sup>st</sup> Century: Mental Illness & Addiction. 75<sup>th</sup> Anniversary of the U of Toronto's Dept of Psychiatry, November 2000.
83. Psychopharmacology and the Silence of the Cemetery. Grand Rounds Westchester Division, Cornell University, December 2000.
84. The Creation of Depression. Eric T Carlsson Memorial Grand Rounds, Payne Whitney Division, Cornell University, December 2000.
85. Psychotropic Drugs & The Social Contract. Richardson Research Seminar Institute for the History of Psychiatry, Cornell University, December 2000.

86. Psychopharmacology and The Government of the Self. Centre Nationales de Research, Paris, February 2001.
87. The Rise of Corporate Psychiatry. Departments of Psychiatry and Bioethics, University of Minnesota, April 2001.
88. Treating More Patients than Ever Before. 6<sup>th</sup> Hannah International Symposium, April 2001, Toronto.
89. Good Science or Good Business, SSRIs & Suicide. Joint Centre for Bioethics, University of Toronto, April 19<sup>th</sup> 2001.
90. The History of Antidepressant Therapies. Korean Society for Psychiatry, April 27<sup>th</sup> 2001, Seoul.
91. Making an Antipsychotic. First Greek Society of Psychophysiology Meeting, Thessalonika, June 2001.
92. From Neuroleptics to Antipsychotics. World Federation of Biological Psychiatry. July 2001, Berlin.
93. The Drug Dependence at the Heart of European Social Democracy. Royal College of Psychiatrists & World Psychiatric Association Meeting, July 2001, London.
94. Reshaping Personhood and Identity. At Visions of Life, Molecular Politics and Normalisation, Hinxton Hall, Cambridge, July 17<sup>th</sup> 2001.
95. Evidence Biased Psychiatry. BRAF meeting, University College London, September 19<sup>th</sup> 2001.
96. Where Neuroscience and Culture Meet. Robert Mayne Annual Lecture, Trinity College Dublin, September 27<sup>th</sup> 2001
97. What History Teaches Us. Inaugural Meeting of the Irish Psychiatric Association, Kilkenny, October 28<sup>th</sup> 2001.
98. Cognitive Effects of Psychotropic Drugs. UK Psychiatric Pharmacists Annual Meeting, Reading October 2001.
99. National Institutes of Health Symposium: New Frontiers of Biomedical Research 1945-1980; Psychopharmacology & Behavior, Bethesda, Maryland, Oct 29<sup>th</sup> 2001.
100. McLean Hospital Grand Rounds – Treating More Patients than Ever Before, Boston November 1<sup>st</sup> 2001.
101. Harvard Medical Anthropology Program – Psychopharmacology & The Appearances of Science, November 2<sup>nd</sup> 2001.
102. Social Science: 4S Conference – Analysing Tanya Luhman's In Two Minds, Invited Discussant November 2001.

103. Hidden Effects of Antidepressants. Adverse Reactions to Psychotropic Drugs Meeting, London, November 8<sup>th</sup>.
104. Science and Human Agency: Genes, Drugs and Behaviour. Invited Discussant, Gresham College & The Royal Society, London December 2001.
105. The Appearances of Science – London Medical Sociology Group, January 2002
106. Psychiatry™. The troubled relationship between psychiatry and the pharmaceutical industry. Annual Mind Lecture, Institute of Psychiatry February 2002
107. The Appearances of Science, Bradford University, February 2002.
108. Treating More Patients Than Ever Before, Nottingham, March 2002
109. Science & the Degradation of Psychiatric Care, Invited Plenary Lecture Psychotherapy Section of Royal College of Psychiatrists, Annual Meeting Cambridge April 2002.
110. The Fate of Bipolar Disorders 1900 and 2002 Compared, Yorkshire Section of Royal College of Psychiatrists, April 2002.
111. The New Medical Oikumene. Invited Plenary Lecture, Harvard University Dept of Social Medicine, Workshop on Pharmaceuticals and Globalization. May 2002.
112. The Appearances of Science, University of California, Los Angeles, Dept of Psychiatry, UCLA Medical Classics Lecture, May 2002
113. Evidence Biased Psychiatry, Leading Edge Seminars, Toronto May 2002.
114. Psychopharmacology and the Government of the Self, Public Lecture, Toronto May 2002.
115. Psychopharmacology: What you're not being told. Teesside University Conference – The Fish Ain't Sick, the Water's Dirty, September 2002.
116. Dependence on SSRIs. Addiction Research Forum, Durham, September 2002.
117. This House believes that psychiatry has been compromised by its links with the pharmaceutical industry. Debate in the General and Community Faculty Meeting of the Royal College of Psychiatrists, Newcastle, October 18<sup>th</sup>
118. The Rise of Corporate Psychiatry, Grand Rounds, Ann Arbor, Michigan, October 23<sup>rd</sup> 2002.
119. Psychopharmacology and the Government of the Self. History of Psychiatry Group, Harvard University Faculty Club October 21<sup>st</sup> 2002
120. The Emergence of Corporate Psychiatry Grand Rounds, Cambridge City Hospital. October 29<sup>th</sup> 2002

121. The Corporate Colonisation of the Campus. Queens University, Kingston Ontario, First Annual Lecture on Academic Freedom. November 1<sup>st</sup> 2002.
122. The Silencing of Dissent. Canadian Association of University Teachers' Meeting on Disciplining Dissent Ottawa, November 1-3, 2002.
123. Psychopharmacology in Historical Perspective. History of Psychiatry Group, Cambridge University. November 2002.
124. Drugs – Whose Profit & Whose Loss? Café Scientifique and The Royal Society, Leeds, Nov 18<sup>th</sup>.
125. The not-so-everyday psychopharmacology of everyday nerves. University of Toronto, History of Medicine Conference – the Social Sources of Psychopharmacology, February 25<sup>th</sup> 2003.
126. Risk Societies and the future of psychopharmacology. Dept of Bioethics, University of Toronto, Feb 26<sup>th</sup>, 2003.
127. Brownbag Research Seminars: Grippled by a Python: How Pharmaceutical Companies Control the Medical Marketplace, February 27<sup>th</sup>. York University Toronto
128. That this house believes SSRI treatment causes a significant risk of increased suicidality. Affective Disorders Group, North West, Manchester March 2003.
129. The Creation of Psychopharmacology. Salon International de la Salud, Santiago de Compostella, Spain March 2003.
130. This House believes that Suicide is caused by SSRIs. Irish College of Psychiatrists Dublin March 2003.
131. The Role of New Antipsychotics in Mood Stabilization. Plenary Lecture, General Practice Psychotherapy Association Toronto April 4<sup>th</sup> 2003.
132. Why do we say Doctoring the Data? Robert TM James Memorial Lecture, General Practice Psychotherapy Association Toronto April 3<sup>rd</sup>, 2003.
133. Academic Freedom and your Sex Life. Academic Freedom & The Public Interest, Simon Fraser University, Vancouver, April 25<sup>th</sup>.
134. This House Believes that Antidepressants Cause Dependence. Maudsley Hospital/Institute of Psychiatry, Mental Health Care Debate, July 16<sup>th</sup>, London.
135. Mood Stabilizers: Possible Impact on Service Utilization. British Association for Psychopharmacology – Poster July 2003.
136. Suicide in Schizophrenia. British Association for Psychopharmacology – Poster July 2003.



137. The Construction of the Psychopharmaceutical Marketplace. Plenary Lecture in Vital Politics: Health, Medicine, and Bioeconomics into the 21<sup>st</sup> Century. London School of Economics Sept 2003.
138. The Psychiatric Dance. Theory and Practice of Mental Health Care During the Twentieth Century. U of Amsterdam – Sept 2003.
139. Psychopharmacology and the Government of the Soul. In Stockholm, Swedish Medical Society, Axel and Margaret Ax:son Johnson Foundation, Seminar: From Hysteria to Depression: Modernity & its Discontents. Sept 25<sup>th</sup> 2003.
140. Risk Management: the Way of the future in psychopharmacology. In Stockholm, Swedish Medical Society, Axel and Margaret Ax:son Johnson Foundation, Seminar: From Hysteria to Depression: Modernity & its Discontents. Sept 25<sup>th</sup> 2003.
141. The Construction of the Pharmaceutical Marketplace: Legal Implications. Symposium on Medicine & Industry. 28<sup>th</sup> International Congress on Law & Mental Health Law, Sydney, Sept 2003.
142. Legal Scientism. 28<sup>th</sup> International Congress on Law & Mental Health Law, Sydney, Sept 2003.
143. The Interface between Business and Science. Queensland University of Technology, Guest Lecture, October 2003.
144. Emerging trends in Clinical Litigation. Queensland University of Technology, Faculty of Law. Brisbane, October 2003.
145. Depressed, Bothered and Bewildered. Debate on ABC radio with Ian Hickie, Murdoch University Perth, Australia, October 2003.
146. Shaping the Intimate, Guest Lecture, Murdoch University, Perth, October 2003.
147. Academic Freedom in the New Medical State. University of New Brunswick Academic Freedom Lecture, October 2003.
148. Manufacturing patients, Panel Discussion, University of New Brunswick, October 2003.
149. Psychopharmacology and Freedom. World Mental Health Day, Toronto October 2003.
150. Prozac and Paxil: Fireworks at the medicolegal interface. University of Toronto Faculty of Law Seminar Series, October 2003.
151. The New Language of Marketing. Trent University, Ontario, October 2003.
152. How Pharmaceutical Companies Mould Consciousness. Grand Rounds Neuropsychiatric Institute UCLA, Los Angeles, October 2003.

153. Suicide in the Course of the Treatment of Schizophrenia. Grand Rounds, Harbor-UCLA campus, October 2003.
154. Manufacturing Consensus. Plenary Lecture at Is Psychiatry for Sale, A Mind and Critical Psychiatry Meeting, London, November 17<sup>th</sup>
155. Ghostwriting in the Scientific Marketplace. The political economy of psychiatric drugs and medical authorship. American Anthropological Association Annual Meeting, Chicago, November 19<sup>th</sup> 2003
156. Shaping the Intimate, Bartlett Visiting Professorship, University of Rochester, New York, Nov 22<sup>nd</sup> 2003.
157. Mental Health Service Utilization: 1900 and 2000 Compared. Rochester Psychiatric Institute, Grand Rounds, Nov 22<sup>nd</sup> 2003
158. SSRIs and Suicidal Behavior. Bartlett Visiting Professorship, Workshop, University of Rochester, New York, Nov 23<sup>rd</sup> 2003.
159. The Interface between Academia and Industry. British Association of Pharmaceutical Physicians Annual Meeting, Industry Sponsored Research, Tainted or Unfairly Maligned, Commonwealth Institute, London, January 2004
160. The Fault line in the Drugs Approval System; Risk First, Safety Later, Health Coalition Canada forum, Ottawa, January 28<sup>th</sup> 2004
161. Freud – The Second Coming? What the Antidepressant Story says about Psychoanalysis. Emory University, Atlanta January 2004.
162. The Creation of Depression. Georgia Tech, Atlanta, January 2004.
163. Healy D, Debate: This House Believes that Academic Research in Schizophrenia is in bondage to the pharmaceutical industry. In 12<sup>th</sup> Schizophrenia Annual Winter Workshop, Davos, February.
164. The role of medication in mental health nursing - the Debate. Royal College of Nursing Annual Meeting, Dublin February 2004.
165. How Pharmaceutical Companies Manufacture Cultures. Clinical Trials Research Group, McGill University.
166. Drug Development in Alzheimer's Dementia. Lessons from the History of Drug Development. Johns Hopkins Baltimore March 2004.
167. The impact of psychopharmacology on psychiatry and society. World Psychiatric Association Meeting, Geneva, April 2004.
168. Suicide in the Course of the Treatment of Schizophrenia. American Association for the Advancement of the History of Medicine, Madison Wisconsin April 2004.

169. Marketing Illness. Let Them Eat Prozac. Health Ethics Quarterly Rounds St Boniface Research Centre, Winnipeg May 2004.
170. A conversation with DH. Winnipeg Regional Health Authority, Health Sciences Centre, May 2004.
171. Let Them Eat Prozac, Suicide and Psychotropic Drugs. Nevada State Psychological Association, Annual Conference, Reno Nevada, May 2004.
172. Manufacturing Consensus: The End of Psychiatry as a Science? Scottish Division of Royal College of Psychiatrists, June 2004
173. Schizophrenia: the dangers of current treatments, the need for new approaches. First Horrobin Annual Prize Lecture, London, June 2004.
174. Manufacturing Consensus. How Companies Get Experts Onside. Conference on Integrity in Science Washington July 12<sup>th</sup>.
175. Manufacturing Consensus. American Association for the Advancement of Science Washington July 13<sup>th</sup>.
176. The Creation of Depression. American Psychological Association meeting Honolulu July 2004.
177. Birth, Ritalin, Prozac, Viagra, Death. 4S and EASST meeting Paris August 2004.
178. Manufacturing Consensus. 4S and EASST meeting Paris, August 2004
179. Suicide on Antidepressants. International Society of Pharmacoepidemiology, Bordeaux August 2004.
180. Birth, Ritalin, Prozac, Viagra, Death. In Gender and the Meaning of Mental Health, Ann Arbor, Michigan, October 2004
181. Shaping the Intimate, Culture, Brain and Development Program Hampshire College Amherst, October 2004
182. Psychopharmacology & the Government of the Self. Postgraduate Mental Health Seminar Series, Institute of Social Medicine, Rutgers University October 2004.
183. Manufacturing Consensus, The end of psychiatry as a science? International Center for the Study of Psychiatry and Psychology New York October 2004.
184. The Influence of the Pharmaceutical Industry on Psychiatry. Dept of Psychiatry, Vienna. November 2004.
185. Suicide and SSRIs. Brigham and Women's Dept of Epidemiology Boston January 2005.
186. Madness and Medication. The Third Ronnie Laing Conference, London, March 2005.

187. Birth, Ritalin, Prozac, Viagra, Death. Studium Generale Lecture Groningen April 2005
188. Intimate Psychopharmacology. The Psyences Project, Princeton University April 2005.
189. Manufacturing Consensus. Social Sources of Psychopharmacology, U of Toronto. April 2005
190. Dr Jekyll Takes an SSRI; Antidepressants and Homicide. Social Sources of Psychopharmacology, Toronto April 2005
191. Evidence Based Medicine: how it can be misused. American Psychiatric Association Annual Meeting Atlanta May 2005 Symposium 37A
192. Psychopharmacology and Government of the Self. Grey Nuns Hospital, Edmonton Alberta, May 2005
193. Schizophrenia 1900 and 2000 compared. Third Pierre Flor-Henry Lecture, Edmonton Alberta, May 2005.
194. Notes Toward a History of Mood Stabilizers. Royal College of Psychiatry Annual General Meeting, Edinburgh June 2005
195. Shaping the Intimate. Royal College of Psychiatry Annual General Meeting Edinburgh June 2005.
196. Manufacturing Consensus, Annual Invited Guest Lecture, The Priory Hospitals, London.
197. From Folie Circulaire to Bipolar Disorder, International Association for Law and Mental Health Annual Meeting Paris July 2005.
198. This house believes that evidence based medicine has debased psychiatry. North West Regional Meeting Royal College of Psychiatrists Debate with Clive Adams, Bolton Sept 2005.
199. Cognitive Enhancement: Experience with psychotropics. Sheffield Psychopathology Symposium, Sept 2005.
200. Ethics Roundtable: Hazards and Benefits of Antidepressants. Peter Gaszner, Zoltan Rihmer, Gabor Kovacs, Bela Buda, Jozsef Kovacs: Hungarian Psychopharmacology 8<sup>th</sup> Annual Meeting. Tihany October 2005.
201. Manufacturing Consensus is more important than Manufacturing Drugs. Hungarian Psychopharmacology 8<sup>th</sup> Annual Meeting. Tihany October 2005.
202. To Err is Human: To really foul up needs evidence based medicine. New Philosophies for Community Psychiatry: Recovery-Oriented, Evidence-Based, and Beyond. 8<sup>th</sup> Int Conf on Philosophy, Psychiatry and Psychology, Yale, October 2005

203. Psychopharmacology in Turmoil: a Scientific or Ethical Crisis. PET Seminars, Dept of Public Health, Columbia University New York, October 2005
204. The Root of All Evil: Money, People or Power? Canadian Association of Bioethics, Dalhousie University, October 2005
205. Psychopharmacology in Turmoil: A Scientific or Ethical Crisis. Louisiana State University Dept of Psychology & Philosophy
206. Shaping the Intimate. Chancellor's Distinguished Guest Lecture Louisiana State University, Baton Rouge, October 2005.
207. Birth, Ritalin, Prozac, Viagra and Death. Constructions of Health. U of Sydney Dept of Health Law. November 2005.
208. Antidepressants and Homicide. Medications and Criminal Justice, Institute of Criminology & U of Sydney, Dept of Health Law. November 2005
209. The Medico-Legal consequences of pharmaceutical company involvement in developing new drugs. Adverse Drug Reactions, Litigation and Drug Regulation, Sydney Bar Association, October 2005
210. The consequences of ghostwriting and lack of access to clinical trial data in the medico-legal arena. Expert evidence in Health Law. Faculty of Law University of Sydney, November 2005
211. The psychopharmacology of bipolar disorder. Welsh Psychiatric Society, Llandudno, November 2005.
212. Erasmus Prize Public Debate: Is there a crisis of scientific authority? Simon Schaffer, Steven Shapin, Josee van Eijndhoven, David Healy, Hugh Pennington. De Rode Hoed, Amsterdam November 2005
213. Psychopharmacology in Turmoil: an Ethical or Scientific Crisis. Istituto Superiore de Sanitate, Rome December 16<sup>th</sup> 2005.
214. Psychopharmacology and Modern Cultures. Australian and New Zealand Society for Psychiatry, Psychology and Law, Sydney April 3<sup>rd</sup>
215. Birth, Ritalin, Prozac, Viagra, Death, Royal Adelaide Hospital Grand Round April 4<sup>th</sup>
216. The Latest Mania, Women's & Children's Hospital Grand Round, Adelaide, April 5<sup>th</sup>
217. Suicide rates and other outcomes in Schizophrenia. Royal Adelaide Hospital psych dept internal CME, April 6<sup>th</sup>
218. Antidepressants: Suicidality, Homicidality & Efficacy. RANZCP college CME in conjunction with Healthy Skepticism, April 6<sup>th</sup> - Public Lecture.

219. Suicide rates and other outcomes in Schizophrenia. Flinders Medical Centre Psych Dept CME, April 7<sup>th</sup>
220. Antidepressants & Homicide. Australian and New Zealand Society for Psychiatry, Psychology and Law, Sydney April 8<sup>th</sup>
221. Antidepressants & Homicide. New South Wales Defence Lawyers Forum, Sydney April 10<sup>th</sup>
222. The Latest Mania. First International Conference on Disease Mongering, Plenary Lecture, Newcastle Australia, April 11<sup>th</sup>
223. Melancholia in the 19<sup>th</sup>, 20<sup>th</sup> and 21<sup>st</sup> centuries: similarities and differences. Copenhagen Dept of Psychiatry Symposium on Melancholia, May 2006
224. The New Anecdotes: Evidence Based Medicine and the Degradation of Clinical Practice and Research. In Searching for Gold Standards – the Construction and Governance of RCTs & EBM in Psychiatry. Institute of Psychiatry, June 2006.
225. Bipolar Disorder: a communal disorder. Philosophy, psychiatry and psychology, Leiden University, Holland June 2006.
226. Mood enhancement? Mood Enhancement Workshop. Maastricht, Holland, June 2006.
227. Trussed in Evidence: Guidelines, Tramlines and Faultlines. Health Action International, 25<sup>th</sup> anniversary meeting, Amsterdam, October 2006
228. Ist die Wirkung von Antidepressiva klinisch bedeutsam? Pro Hans-Juergen Moeller, and Thomas Schlaepfer, Con D Healy. Deutsche Gesellschaft fur Psychiatrie, Psychotherapie und Nervenheilkunde, Berlin, Nov 2006
229. Cargo Cult Science. In Perspectives on Scientific Practice from Science and Scientific Studies, Lorentz Center, Leiden University November 2006
230. A Pleasing Look of Truth. Public Lecture, Leiden University November 2006.
231. Global Business Masquerading as Science. The Human Laboratory. Tokyo December 2006
232. Antidepressants and Suicide. Tokyo University December 2006.
233. Antidepressants and Suicide in the Elderly. Welsh Geriatric Society, Caernarfon, March 2007.
234. Mental Health Services in North Wales. Welsh Assembly Government Meeting Caernarfon, March 2007.
235. This House believes that the UK MHRN should have access to data from studies carried out on behalf of pharmaceutical companies? Mental Health Research Network, London, April 2007.

236. Enhancing and stimulating. Second Mood Enhancement Workshop Maastricht April 28<sup>th</sup>
237. Kraepelin's impact on psychiatry. Letten Foundation Meeting Emil Kraepelin's Dichotomy. Ludwig Maximilians Universitat, Munich April 30<sup>th</sup>
238. Trussed in Evidence. UCLA, May 2007.
239. Disease Mongering. American Psychiatric Association Meeting May 2007.
240. The Use of Antidepressants for Anxiety Disorders. Consensus conference on the use of antidepressants for anxiety disorders. Comité d'évaluation des pratiques médicales en matière de médicaments. Brussels May 2007
241. Bipolar Syndrome by Proxy. Pointpark University Pittsburgh June 2007.
242. Cargo Cult Science. McGill Advanced Study Institute, Globalisation and Pharmaceuticals June 2007
243. Brand New Psychiatry. University of Western Ontario, London June 2007
244. Recovery in Psychosis. Royal College of Psychiatrists Annual Meeting Edinburgh 2007.
245. Homicide and Antidepressants. International Association for Law and Mental Health, Padua June.
246. Trussed in Evidence: Ambiguities at the interface between evidence and clinical practice. International Association for Law and Mental Health, Padua June.
247. Tracing pharmaceuticals in South Asia: Regulation, Distribution and Consumption. The Centre for International Public Health Policy. Edinburgh July 2007
248. Academic Stalking. American Psychological Association Annual Meeting San Francisco August 2007.
249. Brand Fascism. Demedicalising misery. University of East London. September 14<sup>th</sup>.
250. Growing up in a Mad World. Wellcome Collection Public Forum, London September 27<sup>th</sup>.
251. Academic Stalking. Canadian Association for University Teachers, Annual Meeting, Ottawa, November 2007.
252. Guerilla guide to mental health systems. Ethics and Mental Health, public lecture, Manchester Metropolitan University.
253. Business as usual. The triumph of pharmacology in mental health care. U of Helsinki, Dept of Sociology November 2007.

254. The Human Laboratory. Patients and the Medico-pharmaceutical complex. Mielenterveysmessut, Helsinki, November 2007
255. Swallowing it whole: this house believes that psychiatrists are unable to resist the seductive messages of the pharmaceutical industry. Institute of Psychiatry, November 2007
256. The Human Laboratory. Public Lecture, University of California, San Diego, December 2007
257. So What's the problem with Ghostwriting? European Medical Writers Association and Institute of Clinical Research, Annual Meeting – Publishing Clinical Trials: Ethics and the Pharmaceutical Industry, February 2008
258. Brand Fascism. European Molecular Biology Lab, Heidelberg April
259. Lowering Suicide Rates: Realistic or Quixotic? Association of European Psychiatrists, Nice 2008
260. Does anything stabilize moods? Royal College of Psychiatrists Annual Meeting London June 2008/
261. Antidepressants and Suicide. CINP Meeting Munich July 2008
262. Trussed in Evidence. European Molecular Biology Summer Workshop, Heidelberg, August 2008
263. Selling out or Win-win: the benefit of industry involvement on training of healthcare providers outweighs the harm? International Association of Medical Science Educators, Salt Lake City, July 2008.
264. Trussed in Evidence. European Molecular Biology Laboratories, Summer Workshop, Heidelberg, August 2008.
265. Can psychiatry play a part in reducing suicide rates? Celtic Conference Royal College of Psychiatrists, Edinburgh September 2008
266. Mania. American College of Neuropsychopharmacology Annual Meeting, Plenary Lecture, Phoenix 2008
267. How marketing created the illusion that antidepressants work. 13<sup>th</sup> National Congress of the Italian Society for Psychopathology (SOPSI) – Rome Feb 13<sup>th</sup> 2009.
268. The Future of Medical Care. Pitzer College, South California, February 2009.
269. From Jekyll and Hyde to Forensic Psychopharmacology. Patton State Hospital. February 2009.
270. The Future of Medical Care. Society and Genetics, UCLA February 2009.



271. Can Obama's Healthcare Plan Work? UCLA, March 2009.
272. Hypnotizing clinicians: the role of statistical significance testing. UCLA/NPI workshop-seminar March 2009
273. Whither Medicine? Eric Nordlander Lecture, Cornell University, New York March 2009.
274. General overview of the history of standardisation in the making and taking of psychotropic drugs. European Science Foundation Workshop on Standardizing Psychoactive Drugs and Drug Uses in the 20<sup>th</sup> Century. Utrecht April 2009.
275. Academic Stalking and Brand Fascism. York University, Toronto, Whistleblower Protection workshop, May 2009
276. The Future of Medical Care. Science and Technology Studies, Global Health Forum, University of California, Davis, May 2009.
277. Does anything stabilize moods? American Psychiatric Association Annual Meeting San Francisco May 2009
278. Psychedelic Psychopharmacotherapy: something old, something new? Royal College of Psychiatrists, Annual Meeting June 2009
279. We're all Indian Now. Tracing Pharmaceuticals in South Asia Workshop, Edinburgh, June 2009
280. Antidepressants and Violence. Broadmoor Hospital, Crowthorpe July 2009.
281. The Future of Medical Care, London Ontario, September 2009
282. Bioethical Devils and Neuroscientific Details. Halifax Bioethics Sept 2009
283. The Future of Medical Care. Grand Rounds, Dalhousie University, Sept 2009
284. The Future of Medical Care. Can Universal Healthcare Survive? University of New Brunswick, Public Lecture, Fredericton, New Brunswick, Sept 2009.
285. Hearts & Minds. Antidepressants in Pregnancy. Fredericton, New Brunswick, Sept 2009.
286. Hearts & Minds. The Risk from MotheRisk. U of Toronto, Oct 2009.
287. The Future of Medical Care. Festschrift for Ruth Kajander, U Western Ontario, London, 2009.
288. The Politics of Evidence. 5<sup>th</sup> Annual Ronald Laing Lecture. Royal College of Psychiatrists, London, October 2009.
289. Antidepressants and Birth Defects. U of Toronto, Jan 2010.

290. Conflict of Interest: The Original Sin? Debate with Arthur Schafer, U of Toronto Jan 15<sup>th</sup>.
291. The Future of Medical Care. University College London, Feb 1<sup>st</sup> 2010.
292. Hearts & Minds. Antidepressants in Pregnancy. Emory University Dept of Public Health March 2010
293. Hearts & Minds. Antidepressants in Pregnancy. Veterans Hospital Grand Rounds, UCLA, March 2010.
294. Hearts & Minds. Antidepressants in Pregnancy. Medwatcher Japan, Annual Symposium, June 2010.
295. The Wisdom of Psychopharmacology. Debate with Dilip Jeste, CINP Meeting Hong Kong 2010.
296. Pharmageddon. University of Paris, Department of Psychiatry. June 2010.
297. The Disappearance of Depression. Tristesse ou Depression, Universite Paris – Rene Descartes, Paris June 2010
298. Lessons from the History of Electroconvulsive Therapy. Royal College of Psychiatrists Annual Meeting Edinburgh 2010.
299. Data Based Medicine. American Psychological Association, Annual Meeting, San Diego, August 2010
300. Data Based Medicine v Evidence Based Medicine. Rigshospitalet Copenhagen, October 2010
301. Ghosts are in the Medical Machine. In Current Challenges in Medical Communication: Diagnosis and Curing of Unethical Practices. Polish Academy of Sciences. Warsaw October 2010
302. The End of Medical Care. Colloque on Science, Clinical Practice and Psychotropic Drugs, Free University of Bruxelles, October 2010.
303. Data Based Medicine v Evidence Based Medicine. Gent October 2010.
304. Is Medicine Terminally Ill? Mario Negri Institute Milan November 2010
305. The History of the Antidepressants: From Switzerland to Japan. The Burgholzli Hospital, Zurich November 2010.
306. The Rise and Fall of the Psychoses. Oslo University, Rikshospitalet December 2010.
307. Antipsychotics and Mental Health Legislation. Norwegian Dept of Health, December 2010.

308. Is Evidence Based Medicine the Enemy of Adverse Event Reporting. Uppsala Monitoring Centre, Uppsala Sweden, February 2011
309. The Changing Face of Psychosis. Therapeutics Initiative, Vancouver March 2011
310. The changing face of psychosis. History of Science Colloquium UCLA March 2011.
311. The changing face of psychosis. Harbor UCLA, March 2011.
312. Is Evidence Based Medicine the Enemy of Good Medical Care, Center for Health Services Research, UCLA, April 2011
313. The Mania for Bipolar Disorder, University of Wisconsin, Milwaukee April 2011.
314. Is Evidence Based Medicine the Enemy of Good Medical Care, Center for Health Services Research, Harbor UCLA, May 2011
315. Ghosts in the Machine. University of Toronto Faculty of Law Meeting on Ghostwriting. May 2011
316. Threats from restrictions to the dissemination of the results of scientific research. In Threats to the Universities, Humanities and Science Conference, London Cambridge July 2011
317. Has Evidence Based Medicine become the problem it was designed to solve. Dunedin School of Medicine, Public Lecture – Department of Bioethics, Sept 2011.
318. The Eclipse of Medical Care. Royal New Zealand College of General Practitioners Annual Meeting Sept 2011.
319. Antidepressants and Suicide. Sponsored by Casper, Auckland Sept 11.
320. The Cardinals of Psychiatry, Health Action International Meeting, Cork Sept 2011.
321. Making Markets. American Association of Anthropology Annual Meeting November 2011
322. Lets have more conflicts of interest. The Scottish Mental Health Research Network. December 2011
323. The Eclipse of Medical Care. Lancaster University Management School – Feb 2012.
324. From Mania to Bipolar Disorder. Lyon. France 2012
325. The Money in Mania. Studium Generale Lecture, Gent, February 2012
326. Hiding the Bodies. Radical Statistics, London, February 2012

327. Quality Prescribing. North Staffordshire Annual Meeting of Non-Medical Prescribers
328. The Changing Face of Psychosis. Tufts University, Boston March 2012.
329. The Psychology of Drugs and Risk. Rutgers University , New Jersey March 2012.
330. The Changing Face of Psychosis. Rutgers University, New Jersey, March 2012
331. The Psychology of Drugs and Risk. City University New York March 2012.
332. The Eclipse of Medical Care. College of Pharmacy U of Toronto March 2012.
333. The Eclipse of Medical Care. McMaster University March 2012.
334. The Psychology of Drugs and Risk, Commonwealth Club San Francisco
335. Antidepressants and Pregnancy, Harbor UCLA March 2012
336. The Changing Face of Psychosis, VA UCLA, March 2012
337. The Psychology of Drugs and Risk. Providence Tarzana UCLA Medical Center March 2012.
338. Professional Suicide? Royal College of Psychiatrists Annual Meeting June 2012.
339. Professional Suicide. APA's Institute of Psychiatric Services Meeting New York, October 2012.
340. Changing Face of Psychosis. Plenary Lecture. APA's Institute of Psychiatric Services Meeting New York, October 2012.
341. The power of the pharmaceutical industry over healthcare. 13<sup>th</sup> Annual Interdisciplinary Research Conference, Trinity College Dublin November
342. RCTs: A gold standard method for hiding adverse events. DUAG symposium, Copenhagen, November 2012
343. The Eclipse of Medicine, American Medical Student Association, Rush University, February 2013.
344. Antidepressants and Homicide. Kent College of Law, Chicago, February 2013
345. Antidepressants and Violence, University of Illinois Chicago, February 2013.
346. Scaremongering: How RxISK will keep us all safe. Selling Sickness, Washington DC February 2013
347. The efficacy of antidepressants. APA annual meeting San Francisco May 2013.
348. Do controlled trials work? Welsh-Breton Psychiatrists Meeting, Dinard June 2013

349. The man who changed psychiatry and the day it changed. Welsh-Breton Psychiatrists Meeting, Dinard June 2013
350. The Creation of Knowledge in Medicine. University of Insubria, Faculty of Medicine Annual Guest Lecture July 2013
351. The Impact of Drugs on Dimensional Aspects of Personality. XIII International Congress on Disorders of Personality, Copenhagen September
352. Antidepressants and the Politics of Health, Portcullis House, All-Party Group on Involuntary Tranquilizer Addiction.
353. Antidepressants and the Politics of Health. Health and Wellbeing Public Lecture Series IV, Bangor University, Llandudno October 2013.
354. Do Antidepressants work? Presidential Debate with Irving Kirsch, Hans-Jurgen Moeller and Elias Erikson Annual DGGPN meeting Berlin November.
355. The Open Society and Drug Transparency. The Open Society, Berlin November
356. The Shipwreck of the Singular. Is Evidence Based Medicine bad for Medicine. St Bartholomew's Global Health Week.
357. Slow Medicine. Centre for Bioethics & Culture, The Sind Institute, Bioethics Seminar – Karachi December
358. The Changing Face of Psychosis, Aga Khan University, Dept of Psychiatry Karachi, December
359. Study 329 and Access to Clinical Trial Data. Agenas, Rome December
360. RCTs as an Act of Authorship. Annual Cochrane Meeting, Napoli, December
361. The Shipwreck of the Singular. Madrid Mental Health Association, February 2014
362. When does my opinion count? Annual Non-Medical Prescriber Meeting, Stafford.
363. Study 329 and Access to Clinical Trial data. Dept of Bioethics. Dalhousie Bioethics Visiting Professorship, March 2014
364. Slow Medicine. Department of Pharmacy and Bioethics. Dalhousie Bioethics Visiting Professorship, March 2014
365. Academic Stalking and Wikipedia Trolling. Dept of Radiology Grand Rounds Dalhousie Bioethics Visiting Professorship, March 2014
366. The Shipwreck of the Singular. Public Lecture. Dalhousie Bioethics Visiting Professorship, March 2014

367. Commercialization and its effects on Academic Medicine. Dept of Bioethics Workshop. Dalhousie Bioethics Visiting Professorship, March 2014
368. Study 329 and Access to Clinical Trial Data. Northern Ireland Medico-Legal Society Annual Meeting, Belfast. March 2014
369. Do Antidepressants work? The Scandinavian Society for Psychopharmacology, April 2014
370. How adverse events can improve clinical practice and advance research. The Mario Negri Institute Milan. April
371. Madness Incorporated: Debate with Richard Bentall and Dinesh Bhugra. How the Light Gets In. Hay-on-Wye Literary Festival, May
372. Docs in the Dock. Debate with Clare Gerada and Gisella Stuart. How the Light Gets In. Hay-on-Wye Literary Festival, May
373. The Persecution of Heretics. How the Light Gets In. Hay-on-Wye Literary Festival, May
374. The role of evidence in clinical practice. European Orthopaedics Meeting London June
375. Authority in Biomedicine, Department of History of Science, UCLA, November
376. Die on Your Feet. International Society for Ethical Psychology and Psychiatry, UCLA November 2014
377. Authorship and Authority in Medicine. Rutgers University November 2014.
378. Die on Your Feet or Live on Your Knees: What does Recovery Mean? FEMHC Conference, Yale University, April 2015
379. Violence & Antidepressants: New Medico-Legal Issues. Medico-Legal Society Meeting of Ireland. Dublin May 2015.
380. Positive Thinking and the Name Game. How the Light Gets In Festival. Hay-on-Wye, Debate with Dinesh Bhugra & Harvi Carel, May 24, 2015.
381. Are Hospitals Bad For Us? How the Light Gets In Festival. Hay-on-Wye, Debate with Natalie Bennett, Diane Abbott, & Mark Salter, May 24, 2015.
382. When the Drugs Don't Work. How the Light Gets In Festival. Hay-on-Wye, May 25, 2015.
- 383.

### **Workshop/Training Programmes**

When psychopharmacology goes wrong. Leading Edge Seminars, Toronto May 2002.

What a therapist needs to know about psychopharmacology. Centre for Training in Psychotherapy, April 23<sup>rd</sup> 2005, Toronto

When psychopharmacotherapy goes wrong. Leading Edge Seminars, Toronto, April 26<sup>th</sup> 2005

One of its outcomes was both the same. Statistical Methods in Psychopharmacology, Welsh Psychiatric Society, November 2005

Antidepressants & Homicide, RANZAPPL, Hunter Valley, April 10-11<sup>th</sup> 2006

How to recognised and deal with the hazards of psychotropic medication. Open Doors, U West of England, Bristol, February 27 2009.

The Marketing of Psychotropic Drugs, University of Minneapolis, May 2009.

In addition to the above, I have lectured in Departmental & Regional forums in

Bradford,  
Bristol (x3),  
Cardiff (x8),  
Cambridge (x4),  
Dumfries  
Edinburgh (x2),  
Wrexham (x2)  
Glasgow  
Leicester,  
Leeds,  
Maastricht,  
Newcastle (x3),  
Northampton  
Norwich  
Oxford,  
Sheffield  
St Bartholomew's,  
The Clarke Institute Toronto (x4),  
The Institute of Psychiatry (x3),  
a number of Irish departmental settings,  
on general practice training schemes in North Wales,  
Royal College of Psychiatrists membership schemes in a number of locations,  
& on several occasions to the Welsh Psychiatric Society.

I have also lectured in a variety of pharmaceutical company sponsored meetings throughout the UK (Newcastle, Glasgow, Cardiff, Bournemouth, Cambridge (x3), Merseyside (x3), London (x3)), as well as in Denmark, Greece (x2), Finland, Italy, Portugal, Spain (x2), Sweden, South Africa & at Satellite Symposia at major meetings such as ECNP & BAP.

Lectures for the most part in these latter forums have been on the history of the antidepressants or antipsychotics or on aspects of the methodologies for evaluating psychotropic efficacy.

I have lectured on a number of occasions for patient groups and for other professionals allied to mental health. Lectures to patient groups have included 3 annual guest lectures for MIND in North Wales.

I have also presented in forums such as the Café Scientifique in Leeds, Sept 1999, and again in November 2002, the British Association for the Advancement of Science, Imperial College, Sept 2000, and on a variety of media programmes dealing with aspects of mental health.

I have lectured at launch meetings for Organon in Athens, Pharmacia in Cambridge, Stockholm, Gothenburg, Malmo, Helsinki, Barcelona, Astra-Zeneca (Germany) in Cambridge, Pierre Fabre in Seoul and London, Astra Zeneca in Athens, Montreux and Seville, and Toronto for Janssen Pharmaceuticals.

I have been consulted on a range of programmes dealing with psychotropic drugs including File on Four, Panorama, Channel 4's The Secret History of Drugs, & Discovery TV's The Psychopharmacological Era, as well as CBC television and radio in Canada, including the Fifth Estate. I have also participated in a nationally broadcast debate on Australia's All in the Mind radio programme on issues surrounding the contemporary use of antidepressants, and participated in ABC in the US 20-20 and CBS programmes on hazards linked to the use of antidepressants.

## **SYMPOSIA & MEETINGS ORGANISED**

I have organised Symposia for BAP Annual Meetings:

- In 1991 on Dementia: Biological Bases
- & Altered Consciousness: Phenomenology and Pharmacology
- In 1992 on: The Circadian System and Affective Disorders
- In 1993 on: Beyond the Receptor: The Significance of Gene Expression for Psychopharmacology
- In 1995 on: Social Phobia.
- In 1996 on: The Psychopharmacology of Aggression
- In 1997 on: Compliance and Psychopharmacology
- In 2000 on: Suicide and Psychotropic Treatment.
- In 2005 on: Dependence & Psychotropic Agents

The North Wales Regional Meeting of the BAP Spring 1992:

- Psychopharmacology: Big Business or Successful Science.
- Psychopharmacology in Primary Care

The BAP Winter Meeting 1993

- Psychotropic Drug Development: Social, Economic & Clinical Issues

A BAP Round-Table on Paediatric Psychopharmacology - London Jan 1997.

- This was attended by an international experts, regulators, the Royal Coll Psychiatrists and the pharmaceutical industry. I organised the meeting and wrote the resulting consensus statement.



For the Royal College of Psychiatrists (RCP)

- I have organised a 1-day meeting & publication of proceedings in Sept 1989, on : History of Biological Psychiatry
- & Symposia for the RCP, Winter Meeting in Glasgow 1995 on: The Relations between Psychiatry and the Pharmaceutical Industry
- & for the Joint RCP & Assoc European Psychiatrists meeting in London 1996 on The History of Physical Treatments in Psychiatry
- & a symposium for the 1998 CINP meeting in Glasgow on: Neuropsychopharmacology: The Historical Record.
- & for the Joint Royal College & World Psychiatric Assoc meeting in London 2001 on: The History of Drug Dependence

For the Int Assoc of Law & Mental Health:

- When medical and legal worlds collide: SSRIs homicide and suicide Paris 2005
- Homicide and Psychotropic Drugs: Padua 2007.

For the World Psychiatric Association Annual Meeting in Buenos Aires Sept 2011 on :  
The Historiography of Mental Illness

## FORMAL TEACHING

In Galway, I taught on pharmacological and psychiatric topics in lecture, seminar and tutorial formats.

In Cambridge I gave lectures, tutorials and clinics to medical students and to candidates on Part I & II MRCPsych courses - covering schizophrenia, the affective disorders, psychopharmacology, substance abuse and the management and assessment of dementia. I was Asst. Tutor to Dr G Berrios for the MRCPsych and was involved in organising and assessing psychiatric and medical student training.

In N Wales, I train medical students from Cardiff and Liverpool, post-graduate psychiatric and GP trainees and contribute to paramedical training.

I have an Honorary appointment with the Dept. of Psychology in Bangor, where from 1990 to 1997 I lectured on abnormal psychology and the history of psychiatry.

I contribute to the College of Medicine's Diploma in Therapeutics, organised by Prof. Philip Routledge.

From 1990 to 2001, I organised a weekly multidisciplinary post-graduate training slot in Bangor with input from national and international guest lecturers.

From 1995 to the present I have organised an annual Guest Lecture slot with contributions from Edward Shorter, Richard Dawkins, Anthony Clare, Roy Porter, Simon Wessely, David Weatherall, David Goldberg & others.

I have lectured on the MRCPsych course for the U of Liverpool from 1997 to the present.

I organise and teach the psychopharmacology module for the U of Birmingham's Diploma in Community Mental Health

From 1992 through to the end of 1997, I was the S.R/Sp.R Programme Director in North Wales. During this time, the rotation expanded from three A.M.I and one learning disability post to seven A.M I and old age posts, one clinical lecturer post, two learning disability posts and there was always at least one research senior registrar.

I have been the N Wales representative on the All-Wales Speciality Training Committee through the process of Calmanisation.

I was also the Audit Convenor in Gwynedd and the medical representative on the Clinical Effectiveness Committee from 1994 to 2001.

### **DEPARTMENTAL & UNIVERSITY DEVELOPMENT IN NORTH WALES**

While Director of the North Wales Department of Psychological Medicine, the complement of Academic Staff increased from 2 Senior Lecturer posts to 4 Senior Lecturer posts, and later to 1 Chair and 3 other senior academic posts.

I have been personally responsible for the recruitment of all other academics in College of Medicine posts in psychiatry in North Wales.

### **DOCTORAL THESES SUPERVISED:**

North West Wales has had no medical student and no formal post-graduate medical training during the period of time that I have been there. There have, furthermore, been no formal arrangements for collaborative research between the College of Medicine and the University of Wales Bangor.

Trainees on the psychiatric training scheme do not choose North Wales for research purposes. There have nevertheless been a relatively high number of trainees who have their names on articles and small though the numbers are there has been a greater proportion of trainees who have gone on to undertake higher research degrees than can be readily found elsewhere.

Dr C F Fear, MD. Cognitive Processes in Obsessive-Compulsive and Delusional Disorders. Awarded August 1995.

Dr B Williams, PhD. The Role of the Person in People Centred Mental Health Care. Awarded. November 1995.

Dr M-A Pasteur, PhD. The Role of Monoamine systems in Memory Functioning. Awarded. November 1995.

Dr R Tranter, PhD, The Role of Personality in Depressive Disorders and their Response to Antidepressants. Awarded December 2008

Tarang Sharma, University of Copenhagen, Adverse Effects of Antidepressants and their Effects on the Quality of Life of Patients

Shubha Srinivasan, Bangor University, Emotional Processing in Mood Disorders

I currently have 2 whole-time research scientists working with me and I am supervising Paul Green & Margaret Harris in PhD programmes.

I have been an external PhD thesis examiner for:

University of London - psychiatry

University of London – psychology

University of New South Wales - history and philosophy of science

Lampeter University - philosophy of science

Brighton University – medical sociology

Copenhagen University – medical sociology

As well as external examiner for final MB exams at St Bartholomew's Hospital 1996-98.

& external examiner on the Aston University's Distance Learning Psychiatric Pharmacy Diploma & Certificate from 2002 – 2005.

**PSYCHOTHERAPY**

I have been the principal grant holder on a project investigating the efficacy of cognitive therapy for delusional disorders. Work in this area and contributions in two books led to an invitation to be keynote speaker on The Psychotherapy of the Psychoses at the thirtieth annual meeting of RANZCP in May of 1995.

Research is also in progress with R Bentall, J Day, A Rogers and others on behavioural determinants of compliance with neuroleptic medication with a view to constructing a management package aimed at enhancing compliance with treatment.

**LEGAL WORK**

I have been the medical expert for the NHS in a series of cases involving LSD therapy given in the 1950s and 1960s taken out against the NHS. These cases settled with a reputed saving to the NHS of several million pounds.

I have also advised the NHS litigation lawyers on pending ECT suits taken out against the NHS, and have given opinions on cases.

I have been instructed by the General Medical Council to offer a legal opinion on a case involving a matter of psychiatric interest.

I have also given medical opinions in a series of cases linked SSRI intake to suicide, violence, dependence and birth defects. These have in general discounted the role of medication in the claimed effects but in a small series of cases I have offered opinions for the claimants/defendants. These cases have led to a first ever verdict against a pharmaceutical company for psychiatric side effects of psychotropic medication. The case series has led to a Book – Let Them Eat Prozac, which aims at contributing original material to the more general debate on issues at the medico-legal interface.

I have been involved in one Canadian patent action, one securities case and more recently a series of cases centering on congenital malformations and their linkage to prenatal antidepressant intake.

**INDUSTRIAL CONSULTANCIES:**

Astra-Zeneca  
Boots Pharmaceuticals  
Eli Lilly  
Janssen Pharmaceuticals  
Lundbeck  
Organon  
Pharmacia-Upjohn  
Rhone-Poulenc Rorer  
SmithKline Beecham

## **CLINICAL SERVICE DEVELOPMENT**

On arriving in North Wales, I established multidisciplinary working in a sectorized service. The clinical service I offer *ab initio* has had a number of interesting features, with patients having copies of all correspondence on them. This has been subject to a number of studies and has given rise to articles listed in the reference section. It has been highly praised by a number of service auditors and others.

Since 1997, I have been the lead consultant for ECT in North-West Wales and have established I believe the first full consultant led ECT service in the UK. All patients are seen by the ECT team prior to treatment, during treatment and subsequently following discharge, with consultant input on all ECT sessions, and former patients involved in aiding the consent process for new referrals.

Since 2002, I have had sessions devoted to the development of a liaison service with the general medical services in Bangor.

As a consequence for the past 8 years, I have been working from 5 to 8 fixed sessions.

Through 1990-94, I was Chairman of the Gwynedd group of psychiatric consultants. During this time, the psychiatric services moved from acute to community unit management and the North Wales psychiatric services adopted Trust status. By virtue of my position, I was centrally involved in developments.

At Directorate level:

From 2002 I have been the Chair of the Local Consultant group.

I chair the Mental Health Clinical Governance Group.

From 2002 to 2007 I was deputy clinical director

On behalf of the North West Wales Trust:

I sit on the Research Committee,

& on the Clinical School Development Committee

& I chair the Research Governance Review Committee;

This latter committee scrutinizes research for compliance with regulations such as the ionizing radiation regulations, human tissue act, capacity and consent, and for cost implications to the clinical service.

My clinical and academic input has been regularly cited as one reason why North West Wales has had all substantive and training posts filled in recent years, and why morale is particularly good in this service.

David Healy

November 19, 2015